{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-047058","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.826610+00:00","generated_at":"2026-06-10T23:02:06.927127+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rani reports 90% success in preclinical RaniPill HC studies; Phase 1 of adalimumab planned","bullets":["RaniPill HC delivered teriparatide in 18/20 administrations across two canine studies, a 90% cumulative success rate.","Payload increased to up to 20 mg, enabling oral delivery of 90+ additional drug candidates.","Fe57 study showed drug absorption comparable to subcutaneous injection.","Next milestone: initiate Phase 1 trial of RT-105 (adalimumab) using RaniPill HC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-047058","json":"https://secwatch.observer/filing/0000950170-23-047058.json","markdown":"https://secwatch.observer/filing/0000950170-23-047058.md","text":"https://secwatch.observer/filing/0000950170-23-047058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023047058/0000950170-23-047058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023047058/rani-20230907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:02:06.927127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}